Atlas Trials

Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)

Clinical trial NCT01779479 · COMPLETED

Trial details

NCT number
NCT01779479
Sponsor
GBG Forschungs GmbH
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Primary Breast Cancer
Start date
2013-02-01
Primary completion
2015-08-01
Enrollment
333

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.